Skip to main content

Table 4 Summary of positive rates of CTL responses to each peptide antigen

From: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Positive rates of CTL responses to each antigen in all patients (n = 11)

Number of vaccination

URLC10 (%)

TTK (%)

KOC1 (%)

VEGFR1 (%)

VEGFR2 (%)

CMV (%)

Pre-vac.

27.3 (3/11)

36.4 (4/11)

40.0 (4/10)

20.0 (2/10)

40.0 (4/10)

100.0 (10/10)

4

70.0 (7/10)

27.3 (3/11)

45.5 (5/11)

33.3 (3/9)

45.5 (5/11)

100.0 (11/11)

8

54.5 (6/11)

36.4 (4/11)

45.5 (5/11)

45.5 (5/11)

36.4 (4/11)

100.0 (11/11)

12

100.0 (5/5)

40.0 (2/5)

60.0 (3/5)

40.0 (2/5)

80.0 (4/5)

100.0 ( 5/ 5)

16

100.0 (5/5)

40.0 (2/5)

60.0 (3/5)

60.0 (3/5)

80.0 (4/5)

100.0 ( 5/ 5)

  1. CTL positive rates on the pre-vaccination, 4th, 8th, 12th or 16th vaccination were examined in all patients (n = 11), CR patients (n = 6) and PD patients (n = 5). When the ELISPOT Assay indicated +, ++ or +++, we judged it to be positive case. *p values.